CJC-1295 + AOD-9604 Stack: Complete Protocol, Dosing, and Evidence

What Is the Rationale for Combining CJC-1295 and AOD-9604?

These two peptides address fat metabolism from different angles. CJC-1295 raises endogenous growth hormone (GH) and IGF-1, which shifts substrate use toward fat oxidation and supports lean-mass preservation. AOD-9604 acts directly on adipose tissue through beta-3 adrenergic-like activity, stimulating lipolysis without raising IGF-1 or blood glucose to any meaningful degree. Stacking them may produce additive fat-loss signaling while limiting the metabolic side effects associated with full-length GH administration.

How CJC-1295 Raises Growth Hormone

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that drives pulsatile GH secretion from the anterior pituitary. The drug-affinity complex (DAC) version extends the half-life to roughly 6-8 days by covalently binding to serum albumin, whereas the non-DAC version (also called Modified GRF 1-29) has a half-life of about 30 minutes [1].

A phase II trial published in the Journal of Clinical Endocrinology and Metabolism (N=65 healthy adults) found that a single 60 mcg/kg dose of CJC-1295 with DAC elevated mean GH concentrations by 2- to 10-fold and sustained elevated IGF-1 levels (by 1.5- to 3-fold above baseline) for 14 days post-injection [1]. That sustained GH pulse differs from the sharp, brief GH spikes produced by GHRP-class peptides such as ipamorelin, which is why many practitioners combine a GHRH analogue with a GHRP rather than using either alone.

How AOD-9604 Targets Fat Directly

AOD-9604 is residues 176-191 of the human growth hormone sequence, modified with a tyrosine addition at the N-terminus to improve stability [2]. Early preclinical work in obese rodent models showed that AOD-9604 reduced body weight by 50% compared to saline controls over 19 days, with no effect on serum IGF-1 and no change in fasting insulin [3].

The key mechanistic distinction: AOD-9604 appears to stimulate lipolysis and inhibit lipogenesis through a receptor pathway that mimics beta-3 adrenergic activation rather than through the GH receptor itself [3]. This is why it does not carry the insulin-resistance risk associated with supraphysiologic full-length GH.

Why the Combination May Offer More Than Either Alone

CJC-1295 raises circulating GH and IGF-1, shifting the body toward anabolic and lipolytic metabolism broadly. AOD-9604 provides a more targeted lipolytic signal at the adipocyte level. Combining them means the systemic GH signal from CJC-1295 is supplemented by a direct adipose-tissue signal from AOD-9604, without meaningfully compounding insulin-resistance risk or IGF-1-driven proliferative effects. This is the mechanistic argument practitioners cite most often, though a direct RCT testing the combination has not been published as of 2025.

Evidence Review: What the Science Actually Shows

Honest framing matters here. Neither CJC-1295 nor AOD-9604 has completed a phase III RCT for body-composition outcomes. Both compounds exist in a regulatory and evidentiary gray zone.

CJC-1295: Human Trial Data

The most-cited human data remain the 2006 Ionescu and Frohman phase II study in JCEM, which demonstrated dose-dependent increases in GH and IGF-1 without serious adverse events at doses up to 60 mcg/kg [1]. No published RCT has measured body composition as a primary endpoint for CJC-1295 alone.

GH itself has a well-documented lipolytic effect. A Cochrane systematic review of GH supplementation in adults with GH deficiency (22 trials, N=1,107) found that GH replacement reduced fat mass by a mean of 3.5 kg and increased lean body mass by 2.1 kg compared to placebo, though the review also noted increased odds of fluid retention and glucose intolerance [4].

Extrapolating from GH-deficiency replacement data to healthy adults using a GHRH analogue at lower doses is mechanistically reasonable but involves several inferential steps that have not been validated in controlled trials.

AOD-9604: Human Trial Data

Metabolic Pharmaceuticals Ltd. Conducted a series of phase II and phase IIb trials in the early 2000s testing AOD-9604 orally for obesity. The largest published result, a 24-week trial (N=300), reported modest weight loss of approximately 2.6 kg vs. 0.8 kg for placebo, P<0.05 [5]. The oral formulation later failed to achieve statistical significance on the primary endpoint in a follow-up phase IIb trial, and development for obesity was discontinued [5].

No published human trials have evaluated subcutaneous AOD-9604 specifically for body composition at the doses currently circulating in peptide-therapy communities (250-500 mcg/day). The animal mechanistic data are stronger than the human clinical data.

The Evidence Gap

The table below summarizes the evidence grade for each component and the stack as a whole using the Oxford Centre for Evidence-Based Medicine (OCEBM) framework:

| Agent | Highest Available Evidence | OCEBM Level | |---|---|---| | CJC-1295 (body composition) | Phase II pharmacokinetic trial | Level 2 (for PK); Level 5 for body composition | | AOD-9604 (fat loss) | Phase IIb RCT (oral, N=300) | Level 2 (oral only) | | CJC-1295 + AOD-9604 (stack) | Mechanistic reasoning, case reports | Level 5 |

Practitioners and patients considering this stack should treat it as an off-label research protocol, not a proven therapy. Any responsible telehealth provider will say exactly that.

Complete Dosing Protocol

The protocol below reflects the most commonly reported clinical parameters used by peptide-prescribing physicians in the United States, synthesized from mechanistic data and practitioner-reported outcomes. It is not derived from a published RCT.

Starting Doses

| Peptide | Starting Dose | Common Range | Route | |---|---|---|---| | CJC-1295 (with DAC) | 300 mcg | 200-600 mcg | Subcutaneous | | AOD-9604 | 300 mcg | 250-500 mcg | Subcutaneous |

CJC-1295 with DAC is typically injected twice per week rather than daily, because its half-life of 6-8 days produces sustained GH elevation with infrequent dosing. The non-DAC version (Mod GRF 1-29), by contrast, is injected once to twice daily to mimic the natural pulsatile pattern.

AOD-9604 is short-lived (half-life approximately 1-2 hours) and is injected daily or on a 5 days on / 2 days off schedule.

Injection Timing

Timing matters for both peptides, because GH release is blunted by elevated blood glucose and insulin. Standard guidance from GH-axis physiology literature is to inject in a fasted state, at least 2 hours after the last meal, and to delay eating for 30-60 minutes after injection [6].

Exercising within 60-90 minutes of injection may amplify the GH pulse. This is consistent with data showing that resistance exercise alone raises GH by 3- to 5-fold above baseline transiently [7].

Practical schedule for CJC-1295 with DAC plus AOD-9604:

• Monday morning (fasted): CJC-1295 300 mcg + AOD-9604 300 mcg, subcutaneous
• Thursday morning (fasted): CJC-1295 300 mcg (DAC; AOD-9604 daily if tolerated)
• Remaining daily mornings: AOD-9604 300 mcg alone

For Mod GRF 1-29 (non-DAC) users who prefer a tighter GH pulse, both peptides are injected once daily on the same 5/2 schedule.

Injection Sites

Rotate between the abdomen (2 inches from the navel), lateral thigh, and the lateral aspect of the upper arm. AOD-9604 is sometimes injected proximal to a target fat depot (for example, the lower abdomen for visceral fat reduction), though direct evidence that injection site determines local lipolytic effect in humans is not established.

Reconstitution

Both peptides are supplied as lyophilized powder. Use bacteriostatic water at a standard concentration of 1 mg per mL (1,000 mcg/mL). For a 300-mcg dose, draw 0.30 mL (30 units on a 100-unit insulin syringe). Store reconstituted peptides at 2-8 degrees Celsius and use within 28-30 days.

Cycle Length and Off-Period

Recommended Cycle Duration

Most practitioners use 12-16 weeks as a full cycle for this stack. GH-axis adaptations (including receptor downregulation and somatostatin feedback) become a practical concern with very long continuous use. The 6-8 day half-life of CJC-1295 with DAC means that GH/IGF-1 levels remain elevated for 2-3 weeks after the last injection even without additional dosing.

A 4-8 week off period between cycles allows the hypothalamic-pituitary-GH axis to re-establish baseline pulsatility. During the off period, some practitioners substitute a standalone GHRP such as ipamorelin at 200-300 mcg nightly to maintain partial GH signaling, though that constitutes a separate off-cycle protocol.

Expected Timeline of Effects

• Weeks 1-2: improved sleep quality and recovery reported by many users
• Weeks 3-6: modest changes in body composition may begin; appetite suppression occasionally noted
• Weeks 8-16: measurable fat-mass reduction if diet and training are maintained

These timelines are practitioner-reported estimates, not controlled-trial endpoints. Individual response varies widely based on baseline GH axis function, diet, exercise, and genetics.

Safety, Side Effects, and Contraindications

Adverse Effects of CJC-1295

The JCEM phase II trial recorded the following in the CJC-1295 with DAC cohort: injection-site reactions in 16% of participants, flushing in 8%, and a transient mild headache in 6%. No serious adverse events were attributed to the drug [1]. The longer concern with any sustained GH-raising agent is insulin resistance and the theoretical risk of proliferative effects mediated by chronically elevated IGF-1.

IGF-1 concentrations above the age-adjusted upper limit of normal (>300 ng/mL in most adults under 50) have been associated in epidemiologic studies with increased colorectal and prostate cancer risk, though causality is not established [8]. Monitoring IGF-1 during a CJC-1295 cycle and keeping it within the upper quartile of the normal range (rather than supraphysiologic) is the standard practice recommendation from GH-prescribing endocrinologists.

Adverse Effects of AOD-9604

The phase IIb oral trials recorded no significant metabolic adverse events and no change in fasting glucose or HbA1c versus placebo [5]. AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA for oral use as a food ingredient in 2014 [9]. That GRAS designation applies to oral ingestion, not subcutaneous injection, and does not constitute approval for any therapeutic indication.

At subcutaneous doses used in peptide therapy, reported adverse effects include mild injection-site erythema and, rarely, transient nausea. Serious adverse events have not been published in peer-reviewed literature, though the absence of large controlled trials limits safety conclusions.

Contraindications

Both compounds should be avoided by:

• Patients with active malignancy or personal history of GH-sensitive cancer
• Pregnant or breastfeeding individuals
• Patients with untreated acromegaly or active pituitary adenoma
• Anyone with a known hypersensitivity to the peptide sequence

CJC-1295 should be used with caution in patients with pre-diabetes or insulin resistance. Baseline fasting glucose and HbA1c are required before starting, per the standard of care for any GH-axis-active compound.

Lab Monitoring Protocol

Regular monitoring is not optional. The minimum lab panel recommended before and during a CJC-1295 plus AOD-9604 cycle:

| Timepoint | Labs | |---|---| | Baseline (before cycle start) | IGF-1, fasting glucose, HbA1c, fasting insulin, lipid panel, CBC, CMP | | Week 8 | IGF-1, fasting glucose, HbA1c | | End of cycle (week 12-16) | Full panel repeated | | 4 weeks post-cycle | IGF-1 to confirm return toward baseline |

Target IGF-1 during the cycle: within the age-adjusted normal range, typically 100-300 ng/mL for adults aged 30-60 [10]. If IGF-1 exceeds the upper limit of normal, reduce CJC-1295 dose by 50 mcg or lengthen the injection interval.

Comparing This Stack to Alternatives

CJC-1295 + Ipamorelin vs. CJC-1295 + AOD-9604

The CJC-1295 / ipamorelin combination is better studied and more commonly prescribed. Ipamorelin is a selective GHRP-2 analogue that produces a clean GH pulse with minimal effect on cortisol or prolactin [11]. The CJC-1295 / ipamorelin stack raises GH through two distinct axes (GHRH and ghrelin-receptor) and is favored when the goal includes sleep quality, recovery, and anti-aging alongside fat loss.

The CJC-1295 / AOD-9604 stack is more specifically targeted at lipolysis. Patients whose primary goal is fat loss and who want to minimize IGF-1 elevation may prefer AOD-9604 as the second agent, since AOD-9604 does not raise IGF-1.

Adding a Third Peptide

Some protocols add ipamorelin or BPC-157 to the CJC-1295 / AOD-9604 stack. Adding ipamorelin (200 mcg nightly) can amplify the GH pulse further and improve sleep. BPC-157 at 250-500 mcg/day targets gut and connective-tissue healing through a distinct mechanism and does not interact directly with the GH axis [12]. Three-peptide stacks increase cost, injection burden, and theoretical interaction complexity. Patients new to peptide therapy should complete at least one solo-peptide or two-peptide cycle before adding a third agent.

Practical Guidance for Patients Starting This Stack

A diet with a modest caloric deficit of 300-500 kcal per day and adequate protein (1.6-2.2 g/kg body weight, per the International Society of Sports Nutrition position stand) will determine most of the fat-loss outcome [13]. Neither CJC-1295 nor AOD-9604 replaces a structured diet; they may shift the rate and substrate of fat loss modestly when diet and training are already dialed in.

Resistance training three to five times per week maximizes the lean-mass-preserving effect of the GH axis signal from CJC-1295. GH's anabolic effect on skeletal muscle is largely IGF-1-mediated and is most active in the presence of mechanical loading [14].

Sleep is not a secondary concern. The largest endogenous GH pulse of the day occurs during slow-wave sleep, typically 60-90 minutes after sleep onset [15]. Poor sleep blunts the GH response to GHRH stimulation and reduces the benefit of CJC-1295. Targeting seven to nine hours of sleep per night is a requirement, not a suggestion, for this stack to work as intended.

Patients should have their IGF-1 tested at week 8. If IGF-1 is above 300 ng/mL, the CJC-1295 dose should be reduced to 200 mcg before the next scheduled injection.